UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 20, 2005
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
0-26642 |
|
87-0494517 |
|
(State or other |
|
(Commission |
|
(IRS Employer |
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (801) 584-3600
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 8.01 |
Other Events |
On June 20, 2005, Myriad Genetics, Inc., announced that results of its Phase 2 clinical trial of Flurizan™ in patients with mild to moderate Alzheimer’s disease will be presented as part of the Alzheimer’s Association International Conference on Prevention of Dementia, in Washington, D.C. The press release is attached hereto as an exhibit to this Current Report on Form 8-K and is being filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K.
|
ITEM 9.01 |
Financial Statements and Exhibits. |
|
(c) |
The following exhibit is filed with this report: |
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
The Registrant’s press release dated June 20, 2005. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MYRIAD GENETICS, INC. |
||
|
|
|
||
|
|
|
||
|
Date: June 20, 2005 |
By: |
/s/ Peter D. Meldrum |
|
|
|
|
Peter D. Meldrum |
|
|
|
|
President and Chief Executive Officer |
|
3
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
The Registrant’s press release dated June 20, 2005. |
4